MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

Products, services, technology

Our lead product, MitoStemX, enhances T cell therapies against cancer and is now available for out-licensing. Looking ahead, we are actively developing Mito-66 for kidney fibrosis and MitoBrain for Alzheimer’s disease, tackling two of the most pressing unmet medical needs.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in